Catalyst Pharmaceuticals Inc (CPRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Catalyst Pharmaceuticals Inc (CPRX) has a cash flow conversion efficiency ratio of 0.059x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($59.59 Million) by net assets ($1.01 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Catalyst Pharmaceuticals Inc (CPRX) defensive interval to measure how many days the company can operate on defensive assets alone.
Catalyst Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Catalyst Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Catalyst Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Catalyst Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
First BanCorp.
NYSE:FBP
|
0.058x |
|
Downer Edi Ltd
AU:DOW
|
0.105x |
|
Mr D I Y Group M Bhd
KLSE:5296
|
0.231x |
|
Godrej Industries Limited
NSE:GODREJIND
|
-0.176x |
|
UCO Bank
NSE:UCOBANK
|
0.060x |
|
Proya Cosmetics Co Ltd Class A
SHG:603605
|
-0.014x |
|
Global Power Synergy PCL
BK:GPSC
|
0.044x |
|
Gaon Cable
KO:000500
|
0.025x |
Annual Cash Flow Conversion Efficiency for Catalyst Pharmaceuticals Inc (2004–2025)
The table below shows the annual cash flow conversion efficiency of Catalyst Pharmaceuticals Inc from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Catalyst Pharmaceuticals Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $954.27 Million | $208.67 Million | 0.219x | -33.65% |
| 2024-12-31 | $727.63 Million | $239.81 Million | 0.330x | -10.98% |
| 2023-12-31 | $387.88 Million | $143.60 Million | 0.370x | -4.16% |
| 2022-12-31 | $300.42 Million | $116.05 Million | 0.386x | +32.34% |
| 2021-12-31 | $206.83 Million | $60.37 Million | 0.292x | +9.92% |
| 2020-12-31 | $169.60 Million | $45.03 Million | 0.266x | -32.77% |
| 2019-12-31 | $87.63 Million | $34.61 Million | 0.395x | +178.03% |
| 2018-12-31 | $50.78 Million | $-25.70 Million | -0.506x | -198.20% |
| 2017-12-31 | $80.96 Million | $-13.74 Million | -0.170x | +62.86% |
| 2016-12-31 | $39.31 Million | $-17.96 Million | -0.457x | -40.72% |
| 2015-12-31 | $55.48 Million | $-18.02 Million | -0.325x | +11.57% |
| 2014-12-31 | $35.24 Million | $-12.94 Million | -0.367x | +20.46% |
| 2013-12-31 | $21.39 Million | $-9.88 Million | -0.462x | -31.32% |
| 2012-12-31 | $14.62 Million | $-5.14 Million | -0.352x | +73.48% |
| 2011-12-31 | $3.76 Million | $-4.99 Million | -1.326x | -94.66% |
| 2010-12-31 | $5.52 Million | $-3.76 Million | -0.681x | +32.48% |
| 2009-12-31 | $7.62 Million | $-7.68 Million | -1.009x | -28.94% |
| 2008-12-31 | $10.56 Million | $-8.26 Million | -0.782x | -188.55% |
| 2007-12-31 | $16.32 Million | $-4.42 Million | -0.271x | -356.52% |
| 2006-12-31 | $19.85 Million | $-1.18 Million | -0.059x | +94.18% |
| 2005-12-31 | $446.46K | $-455.36K | -1.020x | +47.98% |
| 2004-12-31 | $117.58K | $-230.52K | -1.961x | -- |
About Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-met… Read more